AstraZeneca stock forecast: Consolidation near GBX12,547 support

Traders Union
All News
Stocks
AstraZeneca slides 0.76% today at GBX12,592

Highlights

AstraZeneca secured EU approval for Etcamah, expanding its oncology portfolio into the ESR1-mutated breast cancer segment.
This approval grants AstraZeneca access to a new European market, potentially bolstering future targeted therapies revenue.
AZN/GBX trades below key short-term averages with mixed momentum signals, expected to fluctuate within GBX11,583 to GBX13,600 over the next several days.

New EU approval expands oncology options amid muted stock reaction

AstraZeneca has received European Commission approval for Etcamah (camizestrant) to be used in combination with a CDK4/6 inhibitor as a first-line treatment for adult patients with estrogen receptor-positive, HER2-negative advanced breast cancer who develop ESR1 mutations during endocrine therapy, according to Investing.com. This regulatory milestone grants AstraZeneca access to a new market in the EU and expands its oncology portfolio with an additional treatment option for a challenging patient subgroup. The development broadens the company’s revenue base and may support future growth in its targeted therapies business, although the stock price has shown muted movement despite the positive news.

Mixed momentum and support levels shape conflicting intraday signals

On the hourly chart, AZN trades below the MA-20 at 12,600 and above the MA-50 at 12,570, while remaining well below the MA-200 at 13,100. The Ichimoku Kijun serves as immediate support at GBX12,547. Momentum indicators present a mixed picture: MACD shows a strong buy signal, whereas ADX indicates seller dominance. RSI and CCI both report bullish signals, but Stoch RSI is neutral, and Bull/Bear Power registers as overbought, suggesting intraday buying pressure dominates against a backdrop of daily weakness and low volatility.

Upward bias as range narrows and volatility bands define risk

In the short term, AZN is expected to trade within a broad corridor of GBX11,583 to GBX13,600. There is a 71% probability of an upward move, with a sideways scenario forming the baseline. A bullish breakout would target the resistance around GBX13,600, while a bearish case would be triggered by a break below the Ichimoku Kijun or the lower bound of the current volatility band.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s stock under pressure despite positive regulatory news. He believes the European Commission approval for Etcamah strengthens the company’s oncology profile but notes that price action reflects caution, not conviction. Technical indicators are mixed with momentum signals clashing and key moving averages still overhead. "Until AZN clears GBX13,100 on strong momentum, I stay defensive and view any rallies as corrective in nature."

Earlier, analysts noted that AstraZeneca's long-term growth prospects remained intact despite recent setbacks in its late-stage pipeline and share performance. The recent European Commission approval for Etcamah adds a strategic growth opportunity that may help offset existing pipeline challenges, but traders should monitor for a decisive break above resistance levels as confirmation of renewed bullish momentum.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.